UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES
Investment Company Act File Number: 811-05299
T. Rowe Price Science & Technology Fund, Inc.
(Exact name of registrant as specified in charter)
100 East Pratt Street, Baltimore, MD 21202
(Address of principal executive offices)
David Oestreicher
100 East Pratt Street, Baltimore, MD 21202
(Name and address of agent for service)
Registrant’s telephone number, including area code: (410) 345-2000
Date of fiscal year end: December 31
Date of reporting period: June 30, 2024
Item 1. Reports to Shareholders
(a) Report pursuant to Rule 30e-1
Item 1. (b) Notice pursuant to Rule 30e-3.
Not applicable.
Item 2. Code of Ethics.
A code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions is filed as an exhibit to the registrant’s annual Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics during the registrant’s most recent fiscal half-year.
Item 3. Audit Committee Financial Expert.
Disclosure required in registrant’s annual Form N-CSR.
Item 4. Principal Accountant Fees and Services.
Disclosure required in registrant’s annual Form N-CSR.
Item 5. Audit Committee of Listed Registrants.
Not applicable.
Item 6. Investments.
(a) Not applicable. The complete schedule of investments is included in Item 7 of this Form N-CSR.
(b) Not applicable.
Item 7. Financial Statements and Financial Highlights for Open-End Management Investment Companies.
(a – b) Report pursuant to Regulation S-X.
Financial
Highlights
Portfolio
of
Investments
Financial
Statements
and
Notes
Additional
Fund
Information
June
30,
2024
Financial
Statements
and
Other
Information
For
more
insights
from
T.
Rowe
Price
investment
professionals,
go
to
troweprice.com
.
T.
ROWE
PRICE
PRSCX
Science
&
Technology
Fund
–
.
PASTX
Science
&
Technology
Fund–
.
Advisor Class
TSNIX
Science
&
Technology
Fund–
.
I Class
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Financial
Highlights
2
For
a
share
outstanding
throughout
each
period
Investor
Class
6
Months
.
Ended
6/30/24
..
Year
..
..
Ended
.
12/31/23
12/31/22
12/31/21
12/31/20
12/31/19
NET
ASSET
VALUE
Beginning
of
period
$
40.18
$
26.13
$
43.40
$
55.09
$
43.16
$
31.39
Investment
activities
Net
investment
income
(loss)
(1)(2)
(0.06)
(0.04)
(0.18)
(0.08)
0.31
(3)
0.34
(4)
Net
realized
and
unrealized
gain/
loss
10.77
14.09
(15.04)
3.01
19.28
13.96
(5)
Total
from
investment
activities
10.71
14.05
(15.22)
2.93
19.59
14.30
Distributions
Net
investment
income
—
—
—
—
(0.30)
(0.35)
Net
realized
gain
—
—
(2.05)
(14.62)
(7.36)
(2.18)
Total
distributions
—
—
(2.05)
(14.62)
(7.66)
(2.53)
NET
ASSET
VALUE
End
of
period
$
50.89
$
40.18
$
26.13
$
43.40
$
55.09
$
43.16
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Financial
Highlights
3
For
a
share
outstanding
throughout
each
period
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
Investor
Class
6
Months
.
Ended
6/30/24
..
Year
..
..
Ended
.
12/31/23
12/31/22
12/31/21
12/31/20
12/31/19
Ratios/Supplemental
Data
Total
return
(2)(6)
26.66%
53.77%
(35.21)%
5.49%
45.80%
45.71%
(5)
Ratios
to
average
net
assets:
(2)
Gross
expenses
before
waivers/
payments
by
Price
Associates
0.79%
(7)
0.81%
0.84%
0.76%
0.77%
0.77%
Net
expenses
after
waivers/
payments
by
Price
Associates
0.79%
(7)
0.81%
0.84%
0.76%
0.77%
0.77%
Net
investment
income
(loss)
(0.24)
%
(7)
(0.10)%
(0.56)%
(0.13)%
0.64%
(3)
0.87%
(4)
Portfolio
turnover
rate
111.2%
186.3%
66.4%
63.3%
65.9%
55.9%
Net
assets,
end
of
period
(in
millions)
$5,898
$4,865
$3,190
$7,892
$8,367
$5,662
0%
0%
0%
0%
0
%
0%
(1)
Per
share
amounts
calculated
using
average
shares
outstanding
method.
(2)
Includes
the
impact
of
expense-related
arrangements
with
Price
Associates.
(3)
Reflects
special
dividends
which
amounted
to
$0.52
per
share
and
1.08%
of
average
net
assets.
(4)
Reflects
special
dividends
which
amounted
to
$0.38
per
share
and
0.96%
of
average
net
assets.
(5)
Includes
a
voluntary
payment
from
Price
Associates
for
the
estimated
effect
of
an
under-
reported
cash
balance
available
for
investment,
representing
$0.02
per
share
based
upon
shares
outstanding
on
the
date
of
payment.
The
payment
increased
total
return
by
0.06%
for
the
year
ended
December
31,
2019.
(6)
Total
return
reflects
the
rate
that
an
investor
would
have
earned
on
an
investment
in
the
fund
during
each
period,
assuming
reinvestment
of
all
distributions,
and
payment
of
no
redemption
or
account
fees,
if
applicable.
Total
return
is
not
annualized
for
periods
less
than
one
year.
(7)
Annualized
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Financial
Highlights
4
For
a
share
outstanding
throughout
each
period
Advisor
Class
6
Months
.
Ended
6/30/24
..
Year
..
..
Ended
.
12/31/23
12/31/22
12/31/21
12/31/20
12/31/19
NET
ASSET
VALUE
Beginning
of
period
$
39.55
$
25.79
$
42.97
$
54.66
$
42.44
$
30.90
Investment
activities
Net
investment
income
(loss)
(1)(2)
(0.11)
(0.12)
(0.26)
(0.25)
0.96
(3)
0.22
(4)
Net
realized
and
unrealized
gain/
loss
10.58
13.88
(14.87)
2.99
18.13
13.73
(5)
Total
from
investment
activities
10.47
13.76
(15.13)
2.74
19.09
13.95
Distributions
Net
investment
income
—
—
—
—
—
(0.23
)
Net
realized
gain
—
—
(2.05)
(14.43)
(6.87)
(2.18)
Total
distributions
—
—
(2.05)
(14.43)
(6.87)
(2.41)
NET
ASSET
VALUE
End
of
period
$
50.02
$
39.55
$
25.79
$
42.97
$
54.66
$
42.44
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Financial
Highlights
5
For
a
share
outstanding
throughout
each
period
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
Advisor
Class
6
Months
.
Ended
6/30/24
..
Year
..
..
Ended
.
12/31/23
12/31/22
12/31/21
12/31/20
12/31/19
Ratios/Supplemental
Data
Total
return
(2)(6)
26.47%
53.35%
(35.35)%
5.19%
45.36%
45.30%
(5)
Ratios
to
average
net
assets:
(2)
Gross
expenses
before
waivers/
payments
by
Price
Associates
1.06%
(7)
1.06%
1.08%
1.06%
1.05%
1.05%
Net
expenses
after
waivers/
payments
by
Price
Associates
1.06%
(7)
1.06%
1.08%
1.06%
1.05%
1.05%
Net
investment
income
(loss)
(0.51)%
(7)
(0.35)%
(0.80)%
(0.43)%
2.28%
(3)
0.57%
(4)
Portfolio
turnover
rate
111.2%
186.3%
66.4%
63.3%
65.9%
55.9%
Net
assets,
end
of
period
(in
thousands)
$66,921
$55,403
$36,812
$71,021
$80,053
$693,750
0%
0%
0%
0%
0%
0%
(1)
Per
share
amounts
calculated
using
average
shares
outstanding
method.
(2)
Includes
the
impact
of
expense-related
arrangements
with
Price
Associates.
(3)
Reflects
special
dividends
which
amounted
to
$0.45
per
share
and
1.08%
of
average
net
assets.
(4)
Reflects
special
dividends
which
amounted
to
$0.37
per
share
and
0.96%
of
average
net
assets.
(5)
Includes
a
voluntary
payment
from
Price
Associates
for
the
estimated
effect
of
an
under-
reported
cash
balance
available
for
investment,
representing
$0.02
per
share
based
upon
shares
outstanding
on
the
date
of
payment.
The
payment
increased
total
return
by
0.06%
for
the
year
ended
December
31,
2019.
(6)
Total
return
reflects
the
rate
that
an
investor
would
have
earned
on
an
investment
in
the
fund
during
each
period,
assuming
reinvestment
of
all
distributions,
and
payment
of
no
redemption
or
account
fees,
if
applicable.
Total
return
is
not
annualized
for
periods
less
than
one
year.
(7)
Annualized
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Financial
Highlights
6
For
a
share
outstanding
throughout
each
period
I
Class
6
Months
.
Ended
6/30/24
..
Year
..
..
Ended
.
12/31/23
12/31/22
12/31/21
12/31/20
12/31/19
NET
ASSET
VALUE
Beginning
of
period
$
40.27
$
26.16
$
43.37
$
55.09
$
43.15
$
31.37
Investment
activities
Net
investment
income
(loss)
(1)(2)
(0.03)
0.01
(0.12)
0.01
0.34
(3)
0.40
(4)
Net
realized
and
unrealized
gain/
loss
10.79
14.10
(15.04)
2.98
19.31
13.95
(5)
Total
from
investment
activities
10.76
14.11
(15.16)
2.99
19.65
14.35
Distributions
Net
investment
income
—
—
—
—
(0.35)
(0.39)
Net
realized
gain
—
—
(2.05)
(14.71)
(7.36)
(2.18)
Total
distributions
—
—
(2.05)
(14.71)
(7.71)
(2.57)
NET
ASSET
VALUE
End
of
period
$
51.03
$
40.27
$
26.16
$
43.37
$
55.09
$
43.15
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Financial
Highlights
7
For
a
share
outstanding
throughout
each
period
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
I
Class
6
Months
.
Ended
6/30/24
..
Year
..
..
Ended
.
12/31/23
12/31/22
12/31/21
12/31/20
12/31/19
Ratios/Supplemental
Data
Total
return
(2)(6)
26.72%
53.94%
(35.09)%
5.60%
45.96%
45.91%
(5)
Ratios
to
average
net
assets:
(2)
Gross
expenses
before
waivers/
payments
by
Price
Associates
0.68%
(7)
0.69%
0.69%
0.65%
0.65%
0.66%
Net
expenses
after
waivers/
payments
by
Price
Associates
0.68%
(7)
0.69%
0.69%
0.65%
0.65%
0.66%
Net
investment
income
(loss)
(0.12)%
(7)
0.02%
(0.38)%
0.01%
0.70%
(3)
1.01%
(4)
Portfolio
turnover
rate
111.2%
186.3%
66.4%
63.3%
65.9%
55.9%
Net
assets,
end
of
period
(in
thousands)
$3,780,022
$2,820,663
$1,880,889
$886,863
$768,880
$479,290
0%
0%
0%
0%
0%
0%
(1)
Per
share
amounts
calculated
using
average
shares
outstanding
method.
(2)
Includes
the
impact
of
expense-related
arrangements
with
Price
Associates.
(3)
Reflects
special
dividends
which
amounted
to
$0.52
per
share
and
1.08%
of
average
net
assets.
(4)
Reflects
special
dividends
which
amounted
to
$0.38
per
share
and
0.96%
of
average
net
assets.
(5)
Includes
a
voluntary
payment
from
Price
Associates
for
the
estimated
effect
of
an
under-
reported
cash
balance
available
for
investment,
representing
$0.02
per
share
based
upon
shares
outstanding
on
the
date
of
payment.
The
payment
increased
total
return
by
0.06%
for
the
year
ended
December
31,
2019.
(6)
Total
return
reflects
the
rate
that
an
investor
would
have
earned
on
an
investment
in
the
fund
during
each
period,
assuming
reinvestment
of
all
distributions,
and
payment
of
no
redemption
or
account
fees,
if
applicable.
Total
return
is
not
annualized
for
periods
less
than
one
year.
(7)
Annualized
T.
ROWE
PRICE
Science
&
Technology
Fund
June
30,
2024
(Unaudited)
8
Portfolio
of
Investments
‡
Shares
$
Value
(Cost
and
value
in
$000s)
‡
COMMON
STOCKS
99.5%
BUSINESS
SERVICES
0.1%
Business
Services
0.1%
Verisk
Analytics
36,600
9,866
Total
Business
Services
9,866
CONSUMER/RETAIL
0.0%
Consumer
Services
0.0%
Think
&
Learn,
Acquisition
Date:
12/23/20
-
1/15/21,
Cost $11,621
(INR) (1)(2)(3)
7,289
—
Total
Consumer/Retail
—
ENERGY
0.3%
Energy
0.3%
Vertiv
Holdings,
Class
A
374,100
32,386
Total
Energy
32,386
FINANCIAL
SERVICES
0.1%
Other
Financial
Services
0.1%
NU
Holdings,
Class
A (1)
781,900
10,079
Total
Financial
Services
10,079
HARDWARE
19.3%
Consumer
Electronics
14.3%
Apple
6,613,954
1,393,031
1,393,031
Contract
Manufacturing
0.8%
Celestica (1)
1,261,800
72,339
Fabrinet
(1)
26,800
6,560
78,899
Electronic
Equipment
And
Components
0.6%
Coherent (1)
363,400
26,332
MKS
Instruments
234,604
30,635
56,967
Enterprise
Hardware
3.6%
Cognex
95,100
4,447
Dell
Technologies,
Class
C
550,900
75,975
Hewlett
Packard
Enterprise
1,174,800
24,870
HP
576,300
20,182
Insight
Enterprises (1)
14,900
2,956
NetApp
543,000
69,938
Pure
Storage,
Class
A (1)
998,700
64,127
T.
ROWE
PRICE
Science
&
Technology
Fund
9
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Seagate
Technology
Holdings
381,100
39,356
Super
Micro
Computer (1)
24,400
19,992
Western
Digital (1)
416,400
31,551
353,394
Total
Hardware
1,882,291
HEALTH
CARE
1.1%
Pharmaceuticals
1.1%
Eli
Lilly
123,200
111,543
Total
Health
Care
111,543
INDUSTRIALS
0.1%
Aerospace
&
Defense
0.1%
Axon
Enterprise (1)
23,400
6,885
Total
Industrials
6,885
INTERNET
12.6%
China
Internet
Media/Advertising
0.2%
58.com (1)(3)
8,367,978
—
Tencent
Holdings
(HKD)
354,000
16,794
16,794
U.S.
Internet
Media/Advertising
11.4%
Alphabet,
Class
A
888,000
161,749
Alphabet,
Class
C
1,667,400
305,835
AppLovin
,
Class
A (1)
831,600
69,206
Ibotta
,
Class
A (1)
130,964
9,843
Meta
Platforms,
Class
A
916,763
462,250
Pinterest,
Class
A (1)
552,942
24,368
Reddit
,
Class
A (1)
153,100
9,782
Snap,
Class
A (1)
858,900
14,266
Trade
Desk,
Class
A (1)
257,600
25,160
Zeta
Global
Holdings,
Class
A (1)
1,377,800
24,318
1,106,777
U.S.
Internet
Retail
0.5%
Amazon.com (1)
98,100
18,958
Carvana
(1)
234,800
30,223
49,181
U.S.
Internet
Services
0.5%
GoDaddy
,
Class
A (1)
370,353
51,742
51,742
Total
Internet
1,224,494
T.
ROWE
PRICE
Science
&
Technology
Fund
10
Shares
$
Value
(Cost
and
value
in
$000s)
‡
IT
SERVICES
0.6%
IT
Services
0.6%
Fair
Isaac (1)
38,100
56,718
Kyndryl
Holdings (1)
101,000
2,657
Total
IT
Services
59,375
MEDIA
&
ENTERTAINMENT
2.5%
Direct-to-Consumer
Subscription
Services
2.2%
Netflix (1)
229,900
155,155
Spotify
Technology (1)
188,600
59,181
214,336
Video
Gaming
0.3%
Epic
Games,
Acquisition
Date:
6/18/20
-
3/29/21,
Cost $34,497 (1)(2)(3)
53,150
32,060
32,060
Total
Media
&
Entertainment
246,396
SEMICONDUCTORS
31.7%
Analog
Semiconductors
3.4%
Analog
Devices
434,500
99,179
Monolithic
Power
Systems
97,393
80,026
SiTime
(1)
21,400
2,662
Texas
Instruments
766,300
149,068
Wolfspeed
(1)(4)
168,300
3,831
334,766
Digital
Systems
11.4%
NVIDIA
9,009,400
1,113,021
1,113,021
Foundry
0.7%
Taiwan
Semiconductor
Manufacturing,
ADR
371,900
64,640
64,640
Memory
0.3%
Micron
Technology
236,500
31,107
31,107
Microcontrollers
0.8%
Astera
Labs (1)(4)
62,779
3,799
Infineon
Technologies
(EUR)
65,278
2,396
Microchip
Technology
318,700
29,161
NXP
Semiconductors
162,200
43,646
79,002
T.
ROWE
PRICE
Science
&
Technology
Fund
11
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Processors
7.1%
Broadcom
371,000
595,652
Cirrus
Logic (1)
164,900
21,051
QUALCOMM
387,537
77,189
693,892
Semiconductor
Capital
Equipment
7.7%
Applied
Materials
748,400
176,615
ASM
International
(EUR)
34,283
26,205
Axcelis
Technologies (1)
70,900
10,081
Entegris
215,000
29,111
KLA
289,600
238,778
Lam
Research
162,566
173,108
Nova (1)
94,500
22,163
Onto
Innovation (1)
169,500
37,216
Teradyne
224,800
33,336
746,613
Semiconductor
Materials
0.3%
Camtek
(4)
196,000
24,547
24,547
Total
Semiconductors
3,087,588
SOFTWARE
25.9%
Back-Office
Applications
Software
1.2%
Intuit
167,000
109,754
Vertex,
Class
A (1)
200,300
7,221
116,975
Collaboration
and
Productivity
Software
1.8%
Palantir
Technologies,
Class
A (1)
798,600
20,229
ServiceNow
(1)
202,100
158,986
179,215
Design
Software
4.3%
Autodesk (1)
258,800
64,040
Cadence
Design
Systems (1)
420,672
129,462
Synopsys (1)
373,800
222,433
415,935
Front-Office
Applications
Software
3.8%
Adobe (1)
274,300
152,385
HubSpot
(1)
26,800
15,806
Salesforce
789,558
202,995
371,186
T.
ROWE
PRICE
Science
&
Technology
Fund
12
Shares
$
Value
(Cost
and
value
in
$000s)
‡
Industry-Specific
Software
0.4%
Constellation
Software
(CAD)
1,500
4,322
Guidewire
Software (1)
261,100
36,003
40,325
Infrastructure
and
Developer
Tool
Software
12.5%
Datadog
,
Class
A (1)
275,000
35,665
Microsoft
2,324,050
1,038,734
MongoDB (1)
200,600
50,142
Nutanix
,
Class
A (1)
453,100
25,759
Oracle
468,900
66,208
1,216,508
Security
Software
1.9%
Crowdstrike
Holdings,
Class
A (1)
242,600
92,962
Palo
Alto
Networks (1)
237,475
80,506
Zscaler
(1)
54,700
10,513
183,981
Total
Software
2,524,125
TELECOM
EQUIPMENT
5.0%
Wireless
Equipment
0.9%
Motorola
Solutions
217,500
83,966
83,966
Wireline
Equipment
4.1%
Accton
Technology
(TWD)
870,000
14,807
Amphenol,
Class
A
1,827,256
123,102
Arista
Networks (1)
482,000
168,931
Corning
2,364,600
91,865
398,705
Total
Telecom
Equipment
482,671
TELECOM
SERVICES
0.2%
Rest
of
The
World
Telecom
0.2%
ARM
Holdings,
ADR (1)
125,200
20,485
Total
Telecom
Services
20,485
Total
Common
Stocks
(Cost
$6,992,674)
9,698,184
T.
ROWE
PRICE
Science
&
Technology
Fund
13
Shares
$
Value
(Cost
and
value
in
$000s)
‡
CONVERTIBLE
PREFERRED
STOCKS
0.6%
CONSUMER/RETAIL
0.0%
Consumer
Services
0.0%
Think
&
Learn,
Series
F,
Acquisition
Date:
12/23/20,
Cost $14,605
(INR) (1)(2)(3)
4,539
—
Total
Consumer/Retail
—
INDUSTRIALS
0.3%
Transportation
Technology
Services
0.3%
GM
Cruise
Holdings,
Class
F,
Acquisition
Date:
5/7/19,
Cost $21,889 (1)(2)(3)
1,199,400
7,004
Waymo
,
Series
A-2,
Acquisition
Date:
5/8/20,
Cost $25,611 (1)
(2)(3)
298,258
18,403
Waymo
,
Series
B-2,
Acquisition
Date:
6/11/21,
Cost $9,877 (1)
(2)(3)
107,687
6,666
Total
Industrials
32,073
INTERNET
0.2%
Rest
Of
World
Internet
Services
0.2%
Rappi
,
Series
E,
Acquisition
Date:
9/8/20,
Cost $33,355 (1)(2)
(3)
558,273
12,684
Rappi
,
Series
F,
Acquisition
Date:
7/8/21,
Cost $10,111 (1)(2)(3)
156,954
3,566
Total
Internet
16,250
IT
SERVICES
0.1%
Data
Centers
0.1%
Lambda,
Series
C,
Acquisition
Date:
12/28/23,
Cost $10,000 (1)
(2)(3)
653,313
10,000
Total
IT
Services
10,000
Total
Convertible
Preferred
Stocks
(Cost
$125,448)
58,323
SHORT-TERM
INVESTMENTS
0.0%
Money
Market
Funds
0.0%
T.
Rowe
Price
Treasury
Reserve
Fund,
5.37% (5)(6)
2,323,100
2,323
Total
Short-Term
Investments
(Cost
$2,323)
2,323
T.
ROWE
PRICE
Science
&
Technology
Fund
14
Shares
$
Value
(Cost
and
value
in
$000s)
‡
SECURITIES
LENDING
COLLATERAL
0.3%
INVESTMENTS
IN
A
POOLED
ACCOUNT
THROUGH
SECURITIES
LENDING
PROGRAM
WITH
STATE
STREET
BANK
AND
TRUST
COMPANY 0.3%
Money
Market
Funds 0.3%
T.
Rowe
Price
Government
Reserve
Fund,
5.38% (5)(6)
27,024,320
27,024
Total
Investments
in
a
Pooled
Account
through
Securities
Lending
Program
with
State
Street
Bank
and
Trust
Company
27,024
Total
Securities
Lending
Collateral
(Cost
$27,024)
27,024
Total
Investments
in
Securities
100.4%
of
Net
Assets
(Cost
$7,147,469)
$
9,785,854
‡
Shares
are
denominated
in
U.S.
dollars
unless
otherwise
noted.
(1)
Non-income
producing
(2)
Security
cannot
be
offered
for
public
resale
without
first
being
registered
under
the
Securities
Act
of
1933
and
related
rules
("restricted
security").
Acquisition
date
represents
the
day
on
which
an
enforceable
right
to
acquire
such
security
is
obtained
and
is
presented
along
with
related
cost
in
the
security
description.
The
fund
may
have
registration
rights
for
certain
restricted
securities.
Any
costs
related
to
such
registration
are
generally
borne
by
the
issuer.
The
aggregate
value
of
restricted
securities
(excluding
144A
holdings)
at
period
end
amounts
to
$90,383
and
represents
0.9%
of
net
assets.
(3)
See
Note
2.
Level
3
in
fair
value
hierarchy.
(4)
See
Note
3.
All
or
a
portion
of
this
security
is
on
loan
at
June
30,
2024.
(5)
Seven-day
yield
(6)
Affiliated
Companies
ADR
American
Depositary
Receipts
CAD
Canadian
Dollar
EUR
Euro
HKD
Hong
Kong
Dollar
INR
Indian
Rupee
TWD
Taiwan
Dollar
T.
ROWE
PRICE
Science
&
Technology
Fund
15
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
AFFILIATED
COMPANIES
($000s)
The
fund
may
invest
in
certain
securities
that
are
considered
affiliated
companies.
As
defined
by
the
1940
Act,
an
affiliated
company
is
one
in
which
the
fund
owns
5%
or
more
of
the
outstanding
voting
securities,
or
a
company
that
is
under
common
ownership
or
control.
The
following
securities
were
considered
affiliated
companies
for
all
or
some
portion
of
the
six
months
ended
June
30,
2024.
Net
realized
gain
(loss),
investment
income,
change
in
net
unrealized
gain/loss,
and
purchase
and
sales
cost
reflect
all
activity
for
the
period
then
ended.
Affiliate
Net
Realized
Gain
(Loss)
Change
in
Net
Unrealized
Gain/Loss
Investment
Income
T.
Rowe
Price
Government
Reserve
Fund,
5.38%
$
—
$
—
$
—++
T.
Rowe
Price
Treasury
Reserve
Fund,
5.37%
—
—
716
Totals
$
—#
$
—
$
716+
Supplementary
Investment
Schedule
Affiliate
Value
12/31/23
Purchase
Cost
Sales
Cost
Value
06/30/24
T.
Rowe
Price
Government
Reserve
Fund,
5.38%
$
70,442
¤
¤
$
27,024
T.
Rowe
Price
Treasury
Reserve
Fund,
5.37%
203,028
¤
¤
2,323
Total
$
29,347^
#
Capital
gain
distributions
from
underlying
Price
funds
represented
$0
of
the
net
realized
gain
(loss).
++
Excludes
earnings
on
securities
lending
collateral,
which
are
subject
to
rebates
and
fees
as
described
in
Note
3.
+
Investment
income
comprised
$716
of
dividend
income
and
$0
of
interest
income.
¤
Purchase
and
sale
information
not
shown
for
cash
management
funds.
^
The
cost
basis
of
investments
in
affiliated
companies
was
$29,347.
T.
ROWE
PRICE
Science
&
Technology
Fund
June
30,
2024
(Unaudited)
Statement
of
Assets
and
Liabilities
16
($000s,
except
shares
and
per
share
amounts)
Assets
Investments
in
securities,
at
value
(cost
$7,147,469)
$
9,785,854
Receivable
for
investment
securities
sold
298,647
Receivable
for
shares
sold
3,299
Dividends
receivable
1,454
Foreign
currency
(cost
$68)
67
Cash
8
Other
assets
103
Total
assets
10,089,432
Liabilities
Payable
for
investment
securities
purchased
303,860
Obligation
to
return
securities
lending
collateral
27,024
Payable
for
shares
redeemed
6,617
Investment
management
fees
payable
5,017
Due
to
affiliates
354
Payable
to
directors
7
Other
liabilities
1,597
Total
liabilities
344,476
Commitments
and
Contingent
Liabilities
(note
6
)
NET
ASSETS
$
9,744,956
T.
ROWE
PRICE
Science
&
Technology
Fund
June
30,
2024
(Unaudited)
Statement
of
Assets
and
Liabilities
17
($000s,
except
shares
and
per
share
amounts)
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
Net
Assets
Consist
of:
Total
distributable
earnings
(loss)
$
3,021,361
Paid-in
capital
applicable
to
191,291,282
shares
of
$0.01
par
value
capital
stock
outstanding;
1,000,000,000
shares
authorized
6,723,595
NET
ASSETS
$
9,744,956
NET
ASSET
VALUE
PER
SHARE
Investor
Class
(Net
assets:
$5,898,013;
Shares
outstanding:
115,886,139)
$
50.89
Advisor
Class
(Net
assets:
$66,921;
Shares
outstanding:
1,337,745)
$
50.02
I
Class
(Net
assets:
$3,780,022;
Shares
outstanding:
74,067,398)
$
51.03
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Statement
of
Operations
18
($000s)
6
Months
Ended
6/30/24
Investment
Income
(Loss)
Income
Dividend
(net
of
foreign
taxes
of
$204)
$
24,350
Securities
lending
121
Other
14
Total
income
24,485
Expenses
Investment
management
28,046
Shareholder
servicing
Investor
Class
$
4,038
Advisor
Class
51
I
Class
433
4,522
Rule
12b-1
fees
Advisor
Class
75
Prospectus
and
shareholder
reports
Investor
Class
41
Advisor
Class
1
I
Class
4
46
Custody
and
accounting
184
Registration
65
Legal
and
audit
20
Directors
15
Miscellaneous
78
Repaid
to
Price
Associates
177
Total
expenses
33,228
Net
investment
loss
(8,743)
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Statement
of
Operations
19
($000s)
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
6
Months
Ended
6/30/24
Realized
and
Unrealized
Gain
/
Loss
–
Net
realized
gain
(loss)
Securities
746,441
Foreign
currency
transactions
(243)
Net
realized
gain
746,198
Change
in
net
unrealized
gain
/
loss
Securities
1,323,715
Other
assets
and
liabilities
denominated
in
foreign
currencies
90
Change
in
net
unrealized
gain
/
loss
1,323,805
Net
realized
and
unrealized
gain
/
loss
2,070,003
INCREASE
IN
NET
ASSETS
FROM
OPERATIONS
$
2,061,260
T.
ROWE
PRICE
Science
&
Technology
Fund
(Unaudited)
Statement
of
Changes
in
Net
Assets
20
($000s)
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
6
Months
Ended
6/30/24
Year
Ended
12/31/23
Increase
(Decrease)
in
Net
Assets
Operations
Net
investment
loss
$
(
8,743
)
$
(
3,992
)
Net
realized
gain
746,198
594,881
Change
in
net
unrealized
gain
/
loss
1,323,805
2,134,302
Increase
in
net
assets
from
operations
2,061,260
2,725,191
Capital
share
transactions
*
Shares
sold
Investor
Class
453,315
716,072
Advisor
Class
8,115
10,709
I
Class
388,317
378,893
Shares
redeemed
Investor
Class
(
693,994
)
(
762,042
)
Advisor
Class
(
10,637
)
(
11,539
)
I
Class
(
202,494
)
(
424,383
)
Decrease
in
net
assets
from
capital
share
transactions
(
57,378
)
(
92,290
)
Net
Assets
Increase
during
period
2,003,882
2,632,901
Beginning
of
period
7,741,074
5,108,173
End
of
period
$
9,744,956
$
7,741,074
*Share
information
(000s)
Shares
sold
Investor
Class
9,932
20,723
Advisor
Class
178
305
I
Class
8,413
10,648
Shares
redeemed
Investor
Class
(
15,122
)
(
21,733
)
Advisor
Class
(
241
)
(
332
)
I
Class
(
4,387
)
(
12,512
)
Decrease
in
shares
outstanding
(
1,227
)
(
2,901
)
T.
ROWE
PRICE
Science
&
Technology
Fund
Unaudited
NOTES
TO
FINANCIAL
STATEMENTS
21
T.
Rowe
Price
Science
&
Technology
Fund,
Inc. (the
fund) is
registered
under
the
Investment
Company
Act
of
1940
(the
1940
Act)
as a
nondiversified, open-
end
management
investment
company. The
fund
seeks
to
provide
long-term
capital
appreciation.
The
fund
has three classes
of
shares:
the
Science
&
Technology
Fund
(Investor
Class),
the
Science
&
Technology
Fund–
Advisor
Class
(Advisor
Class)
and
the
Science
&
Technology
Fund–I
Class
(I
Class).
Advisor
Class
shares
are
sold
only
through
various
brokers
and
other
financial
intermediaries.
I
Class
shares
require
a
$500,000
initial
investment
minimum,
although
the
minimum
generally
is
waived
or
reduced
for
financial
intermediaries,
eligible
retirement
plans,
and
certain
other
accounts.
The
Advisor
Class
operates
under
a
Board-approved
Rule
12b-1
plan
pursuant
to
which
the
class
compensates
financial
intermediaries
for
distribution,
shareholder
servicing,
and/or
certain
administrative
services;
the
Investor
and
I
Classes
do
not
pay
Rule
12b-1
fees. Each
class
has
exclusive
voting
rights
on
matters
related
solely
to
that
class;
separate
voting
rights
on
matters
that
relate
to
all
classes;
and,
in
all
other
respects,
the
same
rights
and
obligations
as
the
other
classes.
NOTE
1
-
SIGNIFICANT
ACCOUNTING
POLICIES
Basis
of
Preparation
The fund
is
an
investment
company
and
follows
accounting
and
reporting
guidance
in
the
Financial
Accounting
Standards
Board
(FASB)
Accounting
Standards
Codification
Topic
946
(ASC
946).
The
accompanying
financial
statements
were
prepared
in
accordance
with
accounting
principles
generally
accepted
in
the
United
States
of
America
(GAAP),
including,
but
not
limited
to,
ASC
946.
GAAP
requires
the
use
of
estimates
made
by
management.
Management
believes
that
estimates
and
valuations
are
appropriate;
however,
actual
results
may
differ
from
those
estimates,
and
the
valuations
reflected
in
the
accompanying
financial
statements
may
differ
from
the
value
ultimately
realized
upon
sale
or
maturity.
Investment
Transactions,
Investment
Income,
and
Distributions
Investment
transactions
are
accounted
for
on
the
trade
date
basis.
Income
and
expenses
are
recorded
on
the
accrual
basis.
Realized
gains
and
losses
are
reported
on
the
identified
cost
basis. Income
tax-related
interest
and
penalties,
if
incurred,
are
recorded
as
income
tax
expense. Dividends
received
from other
investment
companies are
reflected
as
dividend income;
capital
gain
distributions
are
reflected
as
realized
gain/loss. Dividend
income and
capital
gain
distributions
T.
ROWE
PRICE
Science
&
Technology
Fund
22
are
recorded
on
the
ex-dividend
date. Non-cash
dividends,
if
any,
are
recorded
at
the
fair
market
value
of
the
asset
received. Proceeds
from
litigation
payments,
if
any,
are
included
in
either
net
realized
gain
(loss)
or
change
in
net
unrealized
gain/loss
from
securities. Distributions
to
shareholders
are
recorded
on
the
ex-dividend
date. Income
distributions,
if
any,
are
declared
and
paid
by
each
class annually. A
capital
gain
distribution,
if
any, may
also
be
declared
and
paid
by
the
fund
annually.
Currency
Translation
Assets,
including
investments,
and
liabilities
denominated
in
foreign
currencies
are
translated
into
U.S.
dollar
values
each
day
at
the
prevailing
exchange
rate,
using
the
mean
of
the
bid
and
asked
prices
of
such
currencies
against
U.S.
dollars
as
provided
by
an
outside
pricing
service.
Purchases
and
sales
of
securities,
income,
and
expenses
are
translated
into
U.S.
dollars
at
the
prevailing
exchange
rate
on
the
respective
date
of
such
transaction.
The
effect
of
changes
in
foreign
currency
exchange
rates
on
realized
and
unrealized
security
gains
and
losses
is
not
bifurcated
from
the
portion
attributable
to
changes
in
market
prices.
Class
Accounting
Shareholder
servicing,
prospectus,
and
shareholder
report
expenses
incurred
by
each
class
are
charged
directly
to
the
class
to
which
they
relate.
Expenses
common
to
all
classes,
investment
income,
and
realized
and
unrealized
gains
and
losses
are
allocated
to
the
classes
based
upon
the
relative
daily
net
assets
of
each
class.
The
Advisor
Class
pays
Rule
12b-1
fees,
in
an
amount
not
exceeding
0.25%
of
the
class’s
average
daily
net
assets.
Capital
Transactions
Each
investor’s
interest
in
the
net
assets
of the
fund
is
represented
by
fund
shares. The
fund’s
net
asset
value
(NAV)
per
share
is
computed
at
the
close
of
the
New
York
Stock
Exchange
(NYSE),
normally
4
p.m.
ET,
each
day
the
NYSE
is
open
for
business.
However,
the
NAV
per
share
may
be
calculated
at
a
time
other
than
the
normal
close
of
the
NYSE
if
trading
on
the
NYSE
is
restricted,
if
the
NYSE
closes
earlier,
or
as
may
be
permitted
by
the
SEC.
Purchases
and
redemptions
of
fund
shares
are
transacted
at
the
next-computed
NAV
per
share,
after
receipt
of
the
transaction
order
by
T.
Rowe
Price
Associates,
Inc.,
or
its
agents.
Indemnification
In
the
normal
course
of
business, the
fund
may
provide
indemnification
in
connection
with
its
officers
and
directors,
service
providers,
and/or
private
company
investments. The
fund’s
maximum
exposure
under
these
arrangements
is
unknown;
however,
the
risk
of
material
loss
is
currently
considered
to
be
remote.
T.
ROWE
PRICE
Science
&
Technology
Fund
23
NOTE
2
-
VALUATION
Fair
Value
The
fund’s
financial
instruments
are
valued
at
the
close
of
the
NYSE
and
are
reported
at
fair
value,
which
GAAP
defines
as
the
price
that
would
be
received
to
sell
an
asset
or
paid
to
transfer
a
liability
in
an
orderly
transaction
between
market
participants
at
the
measurement
date. The fund’s
Board
of
Directors
(the
Board)
has
designated
T.
Rowe
Price
Associates,
Inc.
as
the
fund’s
valuation
designee
(Valuation
Designee).
Subject
to
oversight
by
the
Board,
the
Valuation
Designee
performs
the
following
functions
in
performing
fair
value
determinations:
assesses
and
manages
valuation
risks;
establishes
and
applies
fair
value
methodologies;
tests
fair
value
methodologies;
and
evaluates
pricing
vendors
and
pricing
agents.
The
duties
and
responsibilities
of
the
Valuation
Designee
are
performed
by
its
Valuation
Committee. The
Valuation
Designee provides
periodic
reporting
to
the
Board
on
valuation
matters.
Various
valuation
techniques
and
inputs
are
used
to
determine
the
fair
value
of
financial
instruments.
GAAP
establishes
the
following
fair
value
hierarchy
that
categorizes
the
inputs
used
to
measure
fair
value:
Level
1
–
quoted
prices
(unadjusted)
in
active
markets
for
identical
financial
instruments
that
the
fund
can
access
at
the
reporting
date
Level
2
–
inputs
other
than
Level
1
quoted
prices
that
are
observable,
either
directly
or
indirectly
(including,
but
not
limited
to,
quoted
prices
for
similar
financial
instruments
in
active
markets,
quoted
prices
for
identical
or
similar
financial
instruments
in
inactive
markets,
interest
rates
and
yield
curves,
implied
volatilities,
and
credit
spreads)
Level
3
–
unobservable
inputs
(including
the Valuation
Designee’s assumptions
in
determining
fair
value)
Observable
inputs
are
developed
using
market
data,
such
as
publicly
available
information
about
actual
events
or
transactions,
and
reflect
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
Unobservable
inputs
are
those
for
which
market
data
are
not
available
and
are
developed
using
the
best
information
available
about
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
GAAP
requires
valuation
techniques
to
maximize
the
use
of
relevant
observable
inputs
and
minimize
the
use
of
unobservable
inputs.
When
multiple
inputs
are
used
to
derive
fair
value,
the
financial
instrument
is
assigned
to
the
level
within
the
fair
value
hierarchy
based
on
the
lowest-level
input
that
is
significant
to
the
fair
value
of
the
financial
T.
ROWE
PRICE
Science
&
Technology
Fund
24
instrument.
Input
levels
are
not
necessarily
an
indication
of
the
risk
or
liquidity
associated
with
financial
instruments
at
that
level
but
rather
the
degree
of
judgment
used
in
determining
those
values.
Valuation
Techniques
Equity
securities,
including
exchange-traded
funds, listed
or
regularly
traded
on
a
securities
exchange
or
in
the
over-the-
counter
(OTC)
market
are
valued
at
the
last
quoted
sale
price
or,
for
certain
markets,
the
official
closing
price
at
the
time
the
valuations
are
made.
OTC
Bulletin
Board
securities
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices.
A
security
that
is
listed
or
traded
on
more
than
one
exchange
is
valued
at
the
quotation
on
the
exchange
determined
to
be
the
primary
market
for
such
security.
Listed
securities
not
traded
on
a
particular
day
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices
for
domestic
securities
and
the
last
quoted
sale
or
closing
price
for
international
securities.
The
last
quoted
prices
of
non-U.S.
equity
securities
may
be
adjusted
to
reflect
the
fair
value
of
such
securities
at
the
close
of
the
NYSE,
if
the Valuation
Designee
determines
that
developments
between
the
close
of
a
foreign
market
and
the
close
of
the
NYSE
will
affect
the
value
of
some
or
all
of
the
fund’s portfolio
securities.
Each
business
day,
the
Valuation
Designee uses
information
from
outside
pricing
services
to
evaluate
the
quoted
prices
of
portfolio
securities
and,
if
appropriate,
decide whether
it
is
necessary
to
adjust
quoted
prices
to
reflect
fair
value
by
reviewing
a
variety
of
factors,
including
developments
in
foreign
markets,
the
performance
of
U.S.
securities
markets,
and
the
performance
of
instruments
trading
in
U.S.
markets
that
represent
foreign
securities
and
baskets
of
foreign
securities. The Valuation
Designee
uses
outside
pricing
services
to
provide
it
with
quoted
prices
and
information
to
evaluate
or
adjust
those
prices.
The Valuation
Designee
cannot
predict
how
often
it
will
use
quoted
prices
and
how
often
it
will
determine
it
necessary
to
adjust
those
prices
to
reflect
fair
value.
Investments
in
mutual
funds
are
valued
at
the
mutual
fund’s
closing
NAV
per
share
on
the
day
of
valuation.
Assets
and
liabilities
other
than
financial
instruments,
including
short-term
receivables
and
payables,
are
carried
at
cost,
or
estimated
realizable
value,
if
less,
which
approximates
fair
value.
Investments
for
which
market
quotations are
not
readily
available
or
deemed
unreliable
are
valued
at
fair
value
as
determined
in
good
faith
by
the
Valuation
Designee.
The
Valuation
Designee
has
adopted
methodologies
for
determining
the
fair
value
of
investments
for
which
market
quotations
are
not
readily
available
or
deemed
unreliable,
including
the
use
of
other
pricing
sources.
Factors
used
in
determining
fair
value
vary
by
type
of
investment
T.
ROWE
PRICE
Science
&
Technology
Fund
25
and
may
include
market
or
investment
specific
considerations.
The
Valuation
Designee typically
will
afford
greatest
weight
to
actual
prices
in
arm’s
length
transactions,
to
the
extent
they
represent
orderly
transactions
between
market
participants,
transaction
information
can
be
reliably
obtained,
and
prices
are
deemed
representative
of
fair
value.
However,
the
Valuation
Designee may
also
consider
other
valuation
methods
such
as
market-based
valuation
multiples;
a
discount
or
premium
from
market
value
of
a
similar,
freely
traded
security
of
the
same
issuer;
discounted
cash
flows;
yield
to
maturity;
or
some
combination.
Fair
value
determinations
are
reviewed
on
a
regular
basis.
Because
any
fair
value
determination
involves
a
significant
amount
of
judgment,
there
is
a
degree
of
subjectivity
inherent
in
such
pricing
decisions. Fair
value
prices
determined
by
the
Valuation
Designee could
differ
from
those
of
other
market
participants,
and
it
is
possible
that
the
fair
value
determined
for
a
security
may
be
materially
different
from
the
value
that
could
be
realized
upon
the
sale
of
that
security.
Valuation
Inputs
The
following
table
summarizes
the
fund’s
financial
instruments,
based
on
the
inputs
used
to
determine
their
fair
values
on
June
30,
2024
(for
further
detail
by
category,
please
refer
to
the
accompanying
Portfolio
of
Investments):
NOTE
3
-
OTHER
INVESTMENT
TRANSACTIONS
Consistent
with
its
investment
objective, the
fund
engages
in
the
following
practices
to
manage
exposure
to
certain
risks
and/or
to
enhance
performance.
The
investment
objective,
policies,
program,
and
risk
factors
of the
fund
are
described
more
fully
in the
fund’s prospectus
and
Statement
of
Additional
Information.
($000s)
Level
1
Level
2
Level
3
Total
Value
Assets
Common
Stocks
$
9,601,600
$
64,524
$
32,060
$
9,698,184
Convertible
Preferred
Stocks
—
—
58,323
58,323
Short-Term
Investments
2,323
—
—
2,323
Securities
Lending
Collateral
27,024
—
—
27,024
Total
$
9,630,947
$
64,524
$
90,383
$
9,785,854
T.
ROWE
PRICE
Science
&
Technology
Fund
26
Emerging
and
Frontier
Markets
The fund
invests,
either
directly
or
through
investments
in
other
T.
Rowe
Price
funds,
in
securities
of
companies
located
in,
issued
by
governments
of,
or
denominated
in
or
linked
to
the
currencies
of
emerging
and
frontier
market
countries.
Emerging
markets,
and
to
a
greater
extent
frontier
markets, tend
to
have
economic
structures
that
are
less
diverse
and
mature,
less
developed
legal
and
regulatory
regimes,
and
political
systems
that
are
less
stable,
than
those
of
developed
countries.
These
markets
may
be
subject
to
greater
political,
economic,
and
social
uncertainty
and
differing
accounting
standards
and
regulatory
environments
that
may
potentially
impact
the
fund’s
ability
to
buy
or
sell
certain
securities
or
repatriate
proceeds
to
U.S.
dollars.
Emerging
markets
securities
exchanges
are
more
likely
to
experience
delays
with
the
clearing
and
settling
of
trades,
as
well
as
the
custody
of
holdings
by
local
banks,
agents,
and
depositories.
Such
securities
are
often
subject
to
greater
price
volatility,
less
liquidity,
and
higher
rates
of
inflation
than
U.S.
securities.
Investing
in
frontier
markets
is
typically
significantly
riskier
than
investing
in
other
countries,
including
emerging
markets.
Restricted
Securities
The
fund
invests
in
securities
that
are
subject
to
legal
or
contractual
restrictions
on
resale.
Prompt
sale
of
such
securities
at
an
acceptable
price
may
be
difficult
and
may
involve
substantial
delays
and
additional
costs.
Securities
Lending
The fund
may
lend
its
securities
to
approved
borrowers
to
earn
additional
income.
Its
securities
lending
activities
are
administered
by
a
lending
agent
in
accordance
with
a
securities
lending
agreement.
Security
loans
generally
do
not
have
stated
maturity
dates,
and
the
fund
may
recall
a
security
at
any
time.
The
fund
receives
collateral
in
the
form
of
cash
or
U.S.
government
securities.
Collateral
is
maintained
over
the
life
of
the
loan
in
an
amount
not
less
than
the
value
of
loaned
securities;
any
additional
collateral
required
due
to
changes
in
security
values
is
delivered
to
the
fund
the
next
business
day.
Cash
collateral
is
invested
in
accordance
with
investment
guidelines
approved
by
fund
management.
Additionally,
the
lending
agent
indemnifies
the
fund
against
losses
resulting
from
borrower
default.
Although
risk
is
mitigated
by
the
collateral
and
indemnification,
the
fund
could
experience
a
delay
in
recovering
its
securities
and
a
possible
loss
of
income
or
value
if
the
borrower
fails
to
return
the
securities,
collateral
investments
decline
in
value,
and
the
lending
agent
fails
to
perform.
Securities
lending
revenue
consists
of
earnings
on
invested
collateral
and
borrowing
fees,
net
of
any
rebates
to
the
borrower,
compensation
to
the
lending
agent,
and
other
administrative
costs.
In
accordance
with
GAAP,
investments
made
with
cash
collateral
are
reflected
in
the
accompanying
T.
ROWE
PRICE
Science
&
Technology
Fund
27
financial
statements,
but
collateral
received
in
the
form
of
securities
is
not.
At
June
30,
2024,
the
value
of
loaned
securities
was
$26,957,000,
the
value
of
cash
collateral
and
related
investments
was
$27,024,000.
Other
Purchases
and
sales
of
portfolio
securities
other
than
in-kind
transactions,
if
any,
and short-term securities
aggregated $9,742,487,000 and
$9,768,654,000,
respectively,
for
the
six
months ended
June
30,
2024.
NOTE
4
-
FEDERAL
INCOME
TAXES
Generally,
no
provision
for
federal
income
taxes
is
required
since
the
fund
intends
to continue
to
qualify
as
a
regulated
investment
company
under
Subchapter
M
of
the
Internal
Revenue
Code
and
distribute
to
shareholders
all
of
its taxable
income
and
gains.
Distributions
determined
in
accordance
with
federal
income
tax
regulations
may
differ
in
amount
or
character
from
net
investment
income
and
realized
gains
for
financial
reporting
purposes.
Financial
reporting
records
are
adjusted
for
permanent
book/tax
differences
to
reflect
tax
character
but
are
not
adjusted
for
temporary
differences.
The
amount
and
character
of
tax-basis
distributions
and
composition
of
net
assets
are
finalized
at
fiscal
year-end;
accordingly,
tax-basis
balances
have
not
been
determined
as
of
the
date
of
this
report.
The
fund
intends
to
retain
realized
gains
to
the
extent
of
available
capital
loss
carryforwards.
Net
realized
capital
losses
may
be
carried
forward
indefinitely
to
offset
future
realized
capital
gains.
As
of
December
31,
2023,
the
fund
had
$315,963,000
of
available
capital
loss
carryforwards.
At
June
30,
2024,
the
cost
of
investments
(including
derivatives,
if
any)
for
federal
income
tax
purposes
was
$7,188,045,000.
Net
unrealized
gain
aggregated
$2,597,846,000
at
period-end,
of
which
$2,737,129,000
related
to
appreciated
investments
and
$139,283,000
related
to
depreciated
investments.
NOTE
5
-
FOREIGN TAXES
The
fund
is
subject
to
foreign
income
taxes
imposed
by
certain
countries
in
which
it
invests.
Additionally,
capital
gains
realized
upon
disposition
of
securities
issued
in
or
by
certain
foreign
countries
are
subject
to
capital
gains
tax
imposed
by
those
countries.
All
taxes
are
computed
in
accordance
with
the
applicable
foreign
tax
law,
and,
to
the
extent
permitted,
capital
losses
are
used
to
offset
capital
gains.
Taxes
attributable
to
income
are
accrued
by
the
fund
as
a
T.
ROWE
PRICE
Science
&
Technology
Fund
28
reduction
of
income.
Current
and
deferred
tax
expense
attributable
to
capital
gains
is
reflected
as
a
component
of
realized
or
change
in
unrealized
gain/
loss
on
securities
in
the
accompanying
financial
statements.
To
the
extent
that
the
fund
has
country
specific
capital
loss
carryforwards,
such
carryforwards
are
applied
against
net
unrealized
gains
when
determining
the
deferred
tax
liability.
Any
deferred
tax
liability
incurred
by
the
fund
is
included
in
either
Other
liabilities
or
Deferred
tax
liability
on
the
accompanying
Statement
of
Assets
and
Liabilities.
NOTE
6
-
RELATED
PARTY
TRANSACTIONS
The
fund
is
managed
by
T.
Rowe
Price
Associates,
Inc.
(Price
Associates),
a
wholly
owned
subsidiary
of
T.
Rowe
Price
Group,
Inc.
(Price
Group).
The
investment
management
agreement
between
the
fund
and
Price
Associates
provides
for
an
annual
investment
management
fee,
which
is
computed
daily
and
paid
monthly. The
fee
consists
of
an
individual
fund
fee,
equal
to
0.35%
of
the
fund’s
average
daily
net
assets,
and
a
group
fee.
The
group
fee
rate
is
calculated
based
on
the
combined
net
assets
of
certain
mutual
funds
sponsored
by
Price
Associates
(the
group)
applied
to
a
graduated
fee
schedule,
with
rates
ranging
from
0.48%
for
the
first
$1
billion
of
assets
to
0.260%
for
assets
in
excess
of
$845
billion.
The
fund’s
group
fee
is
determined
by
applying
the
group
fee
rate
to
the
fund’s
average
daily
net
assets. At
June
30,
2024,
the
effective
annual
group
fee
rate
was
0.29%.
The Investor
Class and Advisor
Class are
each
subject
to
a
contractual
expense
limitation
through
the
expense
limitation
dates
indicated
in
the
table
below.
This
agreement
will
continue
through
the
expense
limitation
dates
indicated
in
the
table
below,
and
may
be
renewed,
revised,
or
revoked
only
with
approval
of
the
fund’s
Board.
During
the
limitation
period,
Price
Associates
is required
to
waive
or
pay
any
expenses
(excluding
interest;
expenses
related
to
borrowings,
taxes,
and
brokerage;
non-recurring,
extraordinary
expenses;
and
acquired
fund
fees
and
expenses)
that
would
otherwise
cause
the class's ratio
of
annualized
total
expenses
to
average
net
assets
(net
expense
ratio)
to
exceed
its
expense
limitation.
Each
class
is
required
to
repay
Price
Associates
for
expenses
previously
waived/paid
to
the
extent the
class's net
assets
grow
or
expenses
decline
sufficiently
to
allow
repayment
without
causing
the class's net
expense
ratio
(after
the
repayment
is
taken
into
account)
to
exceed
the
lesser
of:
(1)
the
expense
limitation
in
place
at
the
time
such
amounts
were
waived;
or
(2)
the class's
current
expense
limitation.
However,
no
repayment
will
be
made
more
than
three
years
after
the
date
of
a
payment
or
waiver.
T.
ROWE
PRICE
Science
&
Technology
Fund
29
The
I
Class
is
also
subject
to
an
operating
expense
limitation
(I
Class
Limit)
pursuant
to
which
Price
Associates
is
contractually
required
to
pay
all
operating
expenses
of
the
I
Class,
excluding
management
fees;
interest;
expenses
related
to
borrowings,
taxes,
and
brokerage; non-recurring,
extraordinary expenses; and
acquired
fund
fees
and
expenses, to
the
extent
such
operating
expenses,
on
an
annualized
basis,
exceed
the
I
Class
Limit. This
agreement
will
continue
through
the
expense
limitation
date
indicated
in
the
table
below,
and
may
be
renewed,
revised,
or
revoked
only
with
approval
of
the
fund’s
Board.
The
I
Class
is
required
to
repay
Price
Associates
for
expenses
previously
paid
to
the
extent
the
class’s
net
assets
grow
or
expenses
decline
sufficiently
to
allow
repayment
without
causing
the
class’s
operating
expenses
(after
the
repayment
is
taken
into
account)
to
exceed
the
lesser
of:
(1)
the
I
Class
Limit
in
place
at
the
time
such
amounts
were
paid;
or
(2)
the
current
I
Class
Limit.
However,
no
repayment
will
be
made
more
than
three
years
after
the
date
of
a
payment
or
waiver.
Pursuant
to
these
agreements,
expenses
were
waived/paid
by
and/or
repaid
to
Price
Associates
during
the
six
months ended June
30,
2024
as
indicated
in
the
table
below.
At
June
30,
2024,
there
were
no
amounts
subject
to
repayment
by
the
fund.
Any
repayment
of
expenses
previously
waived/paid
by
Price
Associates
during
the
period
would
be
included
in
the
net
investment
income
and
expense
ratios
presented
on
the
accompanying
Financial
Highlights.
In
addition,
the
fund
has
entered
into
service
agreements
with
Price
Associates
and
two
wholly
owned
subsidiaries
of
Price
Associates,
each
an
affiliate
of
the
fund
(collectively,
Price).
Price
Associates
provides
certain
accounting
and
administrative
services
to
the
fund.
T.
Rowe
Price
Services,
Inc.
provides
shareholder
and
administrative
services
in
its
capacity
as
the
fund’s
transfer
and
dividend-disbursing
agent.
T.
Rowe
Price
Retirement
Plan
Services,
Inc.
provides
subaccounting
and
recordkeeping
services
for
certain
retirement
accounts
invested
in
the
Investor
Class
and
Advisor
Class.
For
the
six
months
ended
June
30,
2024,
expenses
incurred
pursuant
to
these
service
agreements
were
$60,000
for
Price
Associates;
$2,319,000
for
T.
Rowe
Price
Services,
Inc.;
Investor
Class
Advisor
Class
I
Class
Expense
limitation/I
Class
Limit
0.99%
1.24%
0.05%
Expense
limitation
date
04/30/26
04/30/26
04/30/26
(Waived)/repaid
during
the
period
($000s)
$—
$—
$177
T.
ROWE
PRICE
Science
&
Technology
Fund
30
and
$429,000
for
T.
Rowe
Price
Retirement
Plan
Services,
Inc.
All
amounts
due
to
and
due
from
Price,
exclusive
of
investment
management
fees
payable,
are
presented
net
on
the
accompanying
Statement
of
Assets
and
Liabilities.
T.
Rowe
Price
Investment
Services,
Inc.
(Investment
Services)
serves
as
distributor
to
the
fund.
Pursuant
to
an
underwriting
agreement,
no
compensation
for
any
distribution
services
provided
is
paid
to
Investment
Services
by
the
fund
(except
for
12b-1
fees
under
a
Board-approved
Rule
12b-1
plan).
Additionally,
the
fund
is
one
of
several
mutual
funds
in
which
certain
college
savings
plans
managed
by
Price
Associates invests.
As
approved
by
the
fund’s
Board
of
Directors,
shareholder
servicing
costs
associated
with
each
college
savings
plan
are
borne
by
the
fund
in
proportion
to
the
average
daily
value
of
its
shares
owned
by
the
college
savings
plan.
Price
has
agreed
to waive/reimburse
shareholder
servicing
costs in
excess
of
0.05%
of
the
fund’s
average
daily
value
of
its
shares
owned
by
the
college
savings
plan.
Any
amounts
waived/
paid
by
Price
under
this
voluntary
agreement
are
not
subject
to
repayment
by
the
fund.
Price
may
amend
or
terminate
this
voluntary
arrangement
at
any
time
without
prior
notice.
For
the
six
months ended
June
30,
2024,
the
fund
was
reimbursed $9,000 for
shareholder
servicing
costs
related
to
the
college
savings
plans, which
is
net
of
a
reimbursement
by
Price
of
$17,000.
All
amounts
due
to
and
due
from
Price,
exclusive
of
investment
management
fees
payable,
are
presented
net
on
the
accompanying
Statement
of
Assets
and
Liabilities. At
June
30,
2024,
approximately
2%
of
the
outstanding
shares
of
the
I
Class
were
held
by
college
savings
plans.
The fund
may
invest
its
cash
reserves
in
certain
open-end
management
investment
companies
managed
by
Price
Associates
and
considered
affiliates
of
the
fund:
the
T.
Rowe
Price
Government
Reserve
Fund
or
the
T.
Rowe
Price
Treasury
Reserve
Fund,
organized
as
money
market
funds
(together,
the
Price
Reserve
Funds).
The
Price
Reserve
Funds
are
offered
as
short-term
investment
options
to
mutual
funds,
trusts,
and
other
accounts
managed
by
Price
Associates
or
its
affiliates
and
are
not
available
for
direct
purchase
by
members
of
the
public.
Cash
collateral
from
securities
lending,
if
any,
is
invested
in
the
T.
Rowe
Price
Government
Reserve Fund. The
Price
Reserve
Funds
pay
no
investment
management
fees.
The fund may
participate
in
securities
purchase
and
sale
transactions
with
other
funds
or
accounts
advised
by
Price
Associates
(cross
trades),
in
accordance
with
procedures
adopted
by the
fund’s
Board
and
Securities
and
Exchange
Commission
rules,
which
require,
among
other
things,
that
such
purchase
and
sale
cross
trades
be
effected
at
the
independent
current
market
price
T.
ROWE
PRICE
Science
&
Technology
Fund
31
of
the
security.
During
the
six
months
ended
June
30,
2024,
the
fund
had
no
purchases
or
sales
cross
trades
with
other
funds
or
accounts
advised
by
Price
Associates.
NOTE
7
-
OTHER
MATTERS
Unpredictable environmental,
political,
social
and
economic
events,
including
but
not
limited
to,
environmental
or
natural
disasters,
war
and
conflict
(including
Russia’s
military
invasion
of
Ukraine
and
the
conflict
in
Israel,
Gaza
and
surrounding
areas),
terrorism,
geopolitical
developments
(including
trading
and
tariff
arrangements,
sanctions
and
cybersecurity
attacks),
and
public
health
epidemics
(including
the
global
outbreak
of
COVID-19)
and
similar
public
health
threats,
may
significantly
affect
the
economy
and
the
markets
and
issuers
in
which
a
fund
invests.
The
extent
and
duration
of
such
events
and
resulting
market
disruptions
cannot
be
predicted.
These
and
other
similar
events
may
cause
instability
across
global
markets,
including
reduced
liquidity
and
disruptions
in
trading
markets,
while
some
events
may
affect
certain
geographic
regions,
countries,
sectors,
and
industries
more
significantly
than
others,
and
exacerbate
other
pre-existing
political,
social,
and
economic
risks.
The
fund’s
performance
could
be
negatively
impacted
if
the
value
of
a
portfolio
holding
were
harmed
by
these
or
such
events.
Management
actively
monitors
the
risks
and
financial
impacts
arising
from
such
events.
T.
ROWE
PRICE
Science
&
Technology
Fund
32
APPROVAL
OF
INVESTMENT
MANAGEMENT
AGREEMENT
Each
year,
the
fund’s
Board
of
Directors
(Board)
considers
the
continuation
of
the
investment
management
agreement
(Advisory
Contract)
between
the
fund
and
its
investment
adviser,
T.
Rowe
Price
Associates,
Inc.
(Adviser).
In
that
regard,
at
a
meeting
held
on
March
11–12,
2024
(Meeting),
the
Board,
including
all
of
the
fund’s
independent
directors
present
in
person
at
the
Meeting,
approved
the
continuation
of
the
fund’s
Advisory
Contract.
At
the
Meeting,
the
Board
considered
the
factors
and
reached
the
conclusions
described
below
relating
to
the
selection
of
the
Adviser
and
the
approval
of
the
Advisory
Contract.
The
independent
directors
were
assisted
in
their
evaluation
of
the
Advisory
Contract
by
independent
legal
counsel
from
whom
they
received
separate
legal
advice
and
with
whom
they
met
separately.
In
providing
information
to
the
Board,
the
Adviser
was
guided
by
a
detailed
set
of
requests
for
information
submitted
by
independent
legal
counsel
on
behalf
of
the
independent
directors.
In
considering
and
approving
the
continuation
of
the
Advisory
Contract,
the
Board
considered
the
information
it
believed
was
relevant,
including,
but
not
limited
to,
the
information
discussed
below.
The
Board
considered
not
only
the
specific
information
presented
in
connection
with
the
Meeting,
but
also
the
knowledge
gained
over
time
through
interaction
with
the
Adviser
about
various
topics.
The
Board
meets
regularly
and,
at
each
of
its
meetings,
covers
an
extensive
agenda
of
topics
and
materials
and
considers
factors
that
are
relevant
to
its
annual
consideration
of
the
renewal
of
the
T.
Rowe
Price
funds’
advisory
contracts,
including
performance
and
the
services
and
support
provided
to
the
funds
and
their
shareholders.
Services
Provided
by
the
Adviser
The
Board
considered
the
nature,
quality,
and
extent
of
the
services
provided
to
the
fund
by
the
Adviser.
These
services
included,
but
were
not
limited
to,
directing
the
fund’s
investments
in
accordance
with
its
investment
program
and
the
overall
management
of
the
fund’s
portfolio,
as
well
as
a
variety
of
related
activities
such
as
financial,
investment
operations,
and
administrative
services;
compliance;
maintaining
the
fund’s
records
and
registrations;
and
shareholder
communications.
The
Board
also
reviewed
the
background
and
experience
of
the
Adviser’s
senior
management
team
and
investment
personnel
involved
in
the
management
of
the
fund,
as
well
as
the
Adviser’s
compliance
record.
The
Board
concluded
that
the
information
it
considered
with
respect
to
the
nature,
quality,
and
extent
of
the
services
provided
by
the
Adviser,
as
well
as
the
other
factors
considered
at
the
Meeting,
supported
the
Board’s
approval
of
the
continuation
of
the
Advisory
Contract.
T.
ROWE
PRICE
Science
&
Technology
Fund
33
Investment
Performance
of
the
Fund
The
Board
took
into
account
discussions
with
the
Adviser
and
detailed
reports
that
it
regularly
receives
throughout
the
year
on
relative
and
absolute
performance
for
the
T.
Rowe
Price
funds.
In
connection
with
the
Meeting,
the
Board
reviewed
information
provided
by
the
Adviser
that
compared
the
fund’s
total
returns,
as
well
as
a
wide
variety
of
other
previously
agreed-upon
performance
measures
and
market
data,
against
relevant
benchmark
indexes
and
peer
groups
of
funds
with
similar
investment
programs
for
various
periods
through
December
31,
2023.
Additionally,
the
Board
reviewed
the
fund’s
relative
performance
information
as
of
September
30,
2023,
which
ranked
the
returns
of
the
fund’s
Investor
Class
for
various
periods
against
a
universe
of
funds
with
similar
investment
programs
selected
by
Broadridge,
an
independent
provider
of
mutual
fund
data.
In
the
course
of
its
deliberations,
the
Board
considered
performance
information
provided
throughout
the
year
and
in
connection
with
the
Advisory
Contract
review
at
the
Meeting,
as
well
as
information
provided
during
investment
review
meetings
conducted
with
portfolio
managers
and
senior
investment
personnel
during
the
course
of
the
year
regarding
the
fund’s
performance.
The
Board
also
considered
relevant
factors,
such
as
overall
market
conditions
and
trends
that
could
adversely
impact
the
fund’s
performance,
the
length
of
the
fund’s
performance
track
record,
and
how
closely
the
fund’s
strategies
align
with
its
benchmarks
and
peer
groups.
The
Board
concluded
that
the
information
it
considered
with
respect
to
the
fund’s
performance,
as
well
as
the
other
factors
considered
at
the
Meeting,
supported
the
Board’s
approval
of
the
continuation
of
the
Advisory
Contract.
Costs,
Benefits,
Profits,
and
Economies
of
Scale
The
Board
reviewed
detailed
information
regarding
the
revenues
received
by
the
Adviser
under
the
Advisory
Contract
and
other
direct
and
indirect
benefits
that
the
Adviser
(and
its
affiliates)
may
have
realized
from
its
relationship
with
the
fund.
In
considering
soft-dollar
arrangements
pursuant
to
which
research
may
be
received
from
broker-dealers
that
execute
the
fund’s
portfolio
transactions,
the
Board
noted
that
during
2023
the
Adviser
paid
the
costs
of
research
services
for
all
client
accounts
that
it
advises,
including
the
T.
Rowe
Price
funds.
However,
effective
January
1,
2024,
the
Adviser
will
begin
using
brokerage
commissions
in
connection
with
certain
T.
Rowe
Price
funds’
securities
transactions
to
pay
for
research
when
permissible.
The
Board
received
information
on
the
estimated
costs
incurred
and
profits
realized
by
the
Adviser
from
managing
the
T.
Rowe
Price
funds.
The
Board
also
reviewed
estimates
of
the
profits
realized
from
managing
the
fund
in
particular,
and
the
Board
concluded
that
the
Adviser’s
profits
were
reasonable
in
light
of
the
services
provided
to
the
fund.
APPROVAL
OF
INVESTMENT
MANAGEMENT
AGREEMENT
(continued)
T.
ROWE
PRICE
Science
&
Technology
Fund
34
The
Board
also
considered
whether
the
fund
benefits
under
the
fee
levels
set
forth
in
the
Advisory
Contract
or
otherwise
from
any
economies
of
scale
realized
by
the
Adviser.
Under
the
Advisory
Contract,
the
fund
pays
a
fee
to
the
Adviser
for
investment
management
services
composed
of
two
components—a
group
fee
rate
based
on
the
combined
average
net
assets
of
most
of
the
T.
Rowe
Price
funds
(including
the
fund)
that
declines
at
certain
asset
levels
and
an
individual
fund
fee
rate
based
on
the
fund’s
average
daily
net
assets—and
the
fund
pays
its
own
expenses
of
operations.
The
group
fee
rate
decreases
as
total
T.
Rowe
Price
fund
assets
grow,
which
reduces
the
management
fee
rate
for
any
fund
that
has
a
group
fee
component
to
its
management
fee,
and
reflects
that
certain
resources
utilized
to
operate
the
fund
are
shared
with
other
T.
Rowe
Price
funds,
thus
allowing
shareholders
of
those
funds
to
share
potential
economies
of
scale.
The
fund’s
shareholders
also
benefit
from
potential
economies
of
scale
through
a
decline
in
certain
operating
expenses
as
the
fund
grows
in
size.
However,
the
fund
is
also
subject
to
contractual
expense
limitations
that
require
the
Adviser
to
waive
its
fees
and/or
bear
any
expenses
that
would
otherwise
cause
the
expenses
of
a
share
class
of
the
fund
to
exceed
a
certain
percentage
based
on
the
class’s
net
assets.
The
expense
limitations
mitigate
the
potential
for
an
increase
in
operating
expenses
above
a
certain
level
that
could
impact
shareholders.
In
addition,
the
Board
noted
that
the
fund
potentially
shares
in
indirect
economies
of
scale
through
the
Adviser’s
ongoing
investments
in
its
business
in
support
of
the
T.
Rowe
Price
funds,
including
investments
in
trading
systems,
technology,
and
regulatory
support
enhancements,
and
the
ability
to
possibly
negotiate
lower
fee
arrangements
with
third-party
service
providers.
The
Board
concluded
that
the
advisory
fee
structure
for
the
fund
provides
for
a
reasonable
sharing
of
benefits
from
any
economies
of
scale
with
the
fund’s
investors.
Fees
and
Expenses
The
Board
was
provided
with
information
regarding
industry
trends
in
management
fees
and
expenses.
Among
other
things,
the
Board
reviewed
data
for
peer
groups
that
were
compiled
by
Broadridge,
which
compared:
(i)
contractual
management
fees,
actual
management
fees,
nonmanagement
expenses,
and
total
expenses
of
the
Investor
Class
of
the
fund
with
a
group
of
competitor
funds
selected
by
Broadridge
(Investor
Class
Expense
Group);
(ii)
actual
management
fees
and
total
expenses
of
the
Advisor
Class
of
the
fund
with
a
group
of
competitor
funds
selected
by
Broadridge
(Advisor
Class
Expense
Group);
and
(iii)
actual
management
fees,
nonmanagement
expenses,
and
total
expenses
of
the
Investor
Class
of
the
fund
with
a
broader
set
of
funds
within
the
Lipper
investment
classification
(Expense
Universe).
The
Board
considered
the
fund’s
contractual
management
fee
rate,
actual
management
fee
rate
(which
reflects
the
management
fees
actually
APPROVAL
OF
INVESTMENT
MANAGEMENT
AGREEMENT
(continued)
T.
ROWE
PRICE
Science
&
Technology
Fund
35
received
from
the
fund
by
the
Adviser
after
any
applicable
waivers,
reductions,
or
reimbursements),
operating
expenses,
and
total
expenses
(which
reflect
the
net
total
expense
ratio
of
the
fund
after
any
waivers,
reductions,
or reimbursements)
in
comparison
with
the
information
for
the
Broadridge
peer
groups.
Broadridge
generally
constructed
the
peer
groups
by
seeking
the
most
comparable
funds
based
on
similar
investment
classifications
and
objectives,
expense
structure,
asset
size,
and
operating
components
and
attributes
and
ranked
funds
into
quintiles,
with
the
first
quintile
representing
the
funds
with
the
lowest
relative
expenses
and
the
fifth
quintile
representing
the
funds
with
the
highest
relative
expenses.
The
information
provided
to
the
Board
indicated
that
the
fund’s
contractual
management
fee
ranked
in
the
second
quintile
(Investor
Class
Expense
Group),
the
fund’s
actual
management
fee
rate
ranked
in
the
first
quintile
(Investor
Class
Expense
Group
and
Advisor
Class
Expense
Group)
and
second
quintile
(Expense
Universe),
and
the
fund’s
total
expenses
ranked
in
the
first
quintile
(Investor
Class
Expense
Group
and
Advisor
Class
Expense
Group)
and
second
quintile
(Expense
Universe).
The
Board
also
reviewed
the
fee
schedules
for
other
investment
portfolios
with
similar
mandates
that
are
advised
or
subadvised
by
the
Adviser
and
its
affiliates,
including
separately
managed
accounts
for
institutional
and
individual
investors;
subadvised
funds;
and
other
sponsored
investment
portfolios,
including
collective
investment
trusts
and
pooled
vehicles
organized
and
offered
to
investors
outside
the
United
States.
Management
provided
the
Board
with
information
about
the
Adviser’s
responsibilities
and
services
provided
to
subadvisory
and
other
institutional
account
clients,
including
information
about
how
the
requirements
and
economics
of
the
institutional
business
are
fundamentally
different
from
those
of
the
proprietary
mutual
fund
business.
The
Board
considered
information
showing
that
the
Adviser’s
mutual
fund
business
is
generally
more
complex
from
a
business
and
compliance
perspective
than
its
institutional
account
business
and
considered
various
relevant
factors,
such
as
the
broader
scope
of
operations
and
oversight,
more
extensive
shareholder
communication
infrastructure,
greater
asset
flows,
heightened
business
risks,
and
differences
in
applicable
laws
and
regulations
associated
with
the
Adviser’s
proprietary
mutual
fund
business.
In
assessing
the
reasonableness
of
the
fund’s
management
fee
rate,
the
Board
considered
the
differences
in
the
nature
of
the
services
required
for
the
Adviser
to
manage
its
mutual
fund
business
versus
managing
a
discrete
pool
of
assets
as
a
subadviser
to
another
institution’s
mutual
fund
or
for
an
institutional
account
and
that
the
Adviser
generally
performs
significant
additional
services
and
assumes
greater
risk
in
managing
the
fund
and
other
T.
Rowe
Price
funds
than
it
does
for
institutional
account
clients,
including
subadvised
funds.
APPROVAL
OF
INVESTMENT
MANAGEMENT
AGREEMENT
(continued)
T.
ROWE
PRICE
Science
&
Technology
Fund
36
On
the
basis
of
the
information
provided
and
the
factors
considered,
the
Board
concluded
that
the
fees
paid
by
the
fund
under
the
Advisory
Contract
are
reasonable.
Approval
of
the
Advisory
Contract
As
noted,
the
Board
approved
the
continuation
of
the
Advisory
Contract.
No
single
factor
was
considered
in
isolation
or
to
be
determinative
to
the
decision.
Rather,
the
Board
concluded,
in
light
of
a
weighting
and
balancing
of
all
factors
considered,
that
it
was
in
the
best
interests
of
the
fund
and
its
shareholders
for
the
Board
to
approve
the
continuation
of
the
Advisory
Contract
(including
the
fees
to
be
charged
for
services
thereunder).
APPROVAL
OF
INVESTMENT
MANAGEMENT
AGREEMENT
(continued)
100
East
Pratt
Street
Baltimore,
MD
21202
T.
Rowe
Price
Investment
Services,
Inc.
Call
1-800-225-5132
to
request
a
prospectus
or
summary
prospectus;
each
includes
investment
objectives,
risks,
fees,
expenses,
and
other
information
that
you
should
read
and
consider
carefully
before
investing.
F61-051
8/24
Item 8. Changes in and Disagreements with Accountants for Open-End Management Investment Companies.
Not applicable.
Item 9. Proxy Disclosures for Open-End Management Investment Companies.
Not applicable.
Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies.
Remuneration paid to Directors is included in Item 7 of this Form N-CSR and/or the Statement of Additional Information.
Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.
If applicable, see Item 7.
Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.
Not applicable.
Item 13. Portfolio Managers of Closed-End Management Investment Companies.
Not applicable.
Item 14. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.
Not applicable.
Item 15. Submission of Matters to a Vote of Security Holders.
There has been no change to the procedures by which shareholders may recommend nominees to the registrant’s board of directors.
Item 16. Controls and Procedures.
(a) The registrant’s principal executive officer and principal financial officer have evaluated the registrant’s disclosure controls and procedures within 90 days of this filing and have concluded that the registrant’s disclosure controls and procedures were effective, as of that date, in ensuring that information required to be disclosed by the registrant in this Form N-CSR was recorded, processed, summarized, and reported timely.
(b) The registrant’s principal executive officer and principal financial officer are aware of no change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.
Not applicable.
Item 18. Recovery of Erroneously Awarded Compensation.
Not applicable.
Item 19. Exhibits.
| (a)(1) | The registrant’s code of ethics pursuant to Item 2 of Form N-CSR is filed with the registrant’s annual Form N-CSR. | |
| (2) | Listing standards relating to recovery of erroneously awarded compensation: Not applicable. | |
| (3) | ||
| (b) | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| T. Rowe Price Science & Technology Fund | ||||
| By | /s/ David Oestreicher |
|||
| David Oestreicher | ||||
| Principal Executive Officer | ||||
| Date | August 20, 2024 | |||
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By | /s/ David Oestreicher |
|||
| David Oestreicher | ||||
| Principal Executive Officer | ||||
| Date | August 20, 2024 |
|||
| By | /s/ Alan S. Dupski |
|||
| Alan S. Dupski | ||||
| Principal Financial Officer | ||||
| Date | August 20, 2024 |
|||